Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Antidepressant discontinuation syndrome

Matthew Gabriel and Verinder Sharma
CMAJ May 29, 2017 189 (21) E747; DOI: https://doi.org/10.1503/cmaj.160991
Matthew Gabriel
London Regional Mental Health Care (Sharma), London, Ont.; University of Ottawa (Gabriel), Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mgabr041@uottawa.ca
Verinder Sharma
London Regional Mental Health Care (Sharma), London, Ont.; University of Ottawa (Gabriel), Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Antidepressant discontinuation syndrome is common

About 20% of patients develop antidepressant discontinuation syndrome following an abrupt stoppage of or marked reduction in the dose of an antidepressant taken continuously for one month.1 Symptoms are usually mild and may occur following treatment with any type of antidepressant. Symptoms occur within two to four days after drug cessation and usually last one to two weeks (occasionally may persist up to one year). If the same or a similar drug is started, the symptoms will resolve within one to three days. Sociodemographic and clinical factors associated with increased vulnerability have not been identified.2 Among the serotonin reuptake inhibitors, paroxetine is associated with the highest incidence of the syndrome and fluoxetine with the lowest. Because of venlafazine’s short half-life, the syndrome may occur more frequently following cessation and symptoms may be more severe.1

Symptoms are vague and variable

Failure to recognize antidepressant discontinuation syndrome may result in medical or psychiatric misdiagnosis. The mnemonic FINISH summarizes the symptoms of antidepressant discontinuation syndrome: Flu-like symptoms (lethargy, fatigue, headache, achiness, sweating), Insomnia (with vivid dreams or nightmares), Nausea (sometimes vomiting), Imbalance (dizziness, vertigo, light-headedness), Sensory disturbances (“burning,” “tingling,” “electric-like” or “shock-like” sensations) and Hyperarousal (anxiety, irritability, agitation, aggression, mania, jerkiness).3

The syndrome needs to be distinguished from relapse

Cessation of antidepressant therapy may increase the risk of relapse of depression or anxiety. Unlike the symptoms of antidepressant discontinuation syndrome, symptoms of relapse usually take more than a few days to appear and to disappear following reintroduction of the antidepressant.4

Patient education may reduce risk

Physicians should be vigilant at times when patients may consider stopping an antidepressant (e.g., during pregnancy). Because not all formulations of the same drug are bioequivalent, there may be an unintended reduction in drug concentration if an antidepressant is switched to another formulation. To minimize risk of the syndrome, patients should be encouraged to consult their physician before stopping an antidepressant. Prescribing an antidepressant with a longer half-life or tapering the medication over six to eight weeks may reduce the risk.4

Treatment of the syndrome needs to be individualized

Management of antidepressant discontinuation syndrome needs to be done on an individual basis because of a lack of specific treatment data (Box 1).2,3,5

Box 1:

Prevention and management of antidepressant discontinuation syndrome2,3,5

  • Tapering may not be necessary for patients taking an antidepressant for less than four weeks or those who are taking fluoxetine.

  • Faster tapering may be possible in cases where doses are low.

  • Antidepressants with short half-lives need to be tapered gradually; however, gradual tapering may not prevent the syndrome in all cases.

  • Patients should be reassured that symptoms are reversible, not life-threatening and usually self-limiting.

  • Switching to fluoxetine when considering stopping another antidepressant may be helpful in some cases.

  • If symptoms are severe, the drug should be reintroduced and a slower taper started.

Footnotes

  • Competing interests: Verinder Sharma has received grants from Assurex, Genome Canada, Neurocrine Biosciences, Stanley Medical Research Institute and Sunovion Pharmaceuticals. No other competing interests were declared.

  • This article has been peer reviewed.

References

  1. ↵
    Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Association; 2013:712–4.
  2. ↵
    1. Fava GA,
    2. Gatti A,
    3. Belaise C,
    4. et al
    . Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015;84:72–81.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Berber MJ
    . FINISH: remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). J Clin Psychiatry 1998;59:255.
    OpenUrlPubMed
  4. ↵
    1. Warner CH,
    2. Bobo W,
    3. Warner C,
    4. et al
    . Antidepressant discontinuation syndrome. Am Fam Physician 2006;74:449–56.
    OpenUrlPubMed
  5. ↵
    1. Ogle NR,
    2. Akkerman S
    . Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract 2013;26:389–96.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (21)
CMAJ
Vol. 189, Issue 21
29 May 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antidepressant discontinuation syndrome
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antidepressant discontinuation syndrome
Matthew Gabriel, Verinder Sharma
CMAJ May 2017, 189 (21) E747; DOI: 10.1503/cmaj.160991

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Antidepressant discontinuation syndrome
Matthew Gabriel, Verinder Sharma
CMAJ May 2017, 189 (21) E747; DOI: 10.1503/cmaj.160991
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Antidepressant discontinuation syndrome is common
    • Symptoms are vague and variable
    • The syndrome needs to be distinguished from relapse
    • Patient education may reduce risk
    • Treatment of the syndrome needs to be individualized
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Antidepressants Produce Persistent G{alpha}s-Associated Signaling Changes in Lipid Rafts after Drug Withdrawal
  • It Is Not Necessary to Discontinue Seizure Threshold-Lowering Medications Prior to Myelography
  • Google Scholar

More in this TOC Section

  • Chronic cutaneous ulcer from drug use
  • A low-barrier, flexible safe supply program to prevent deaths from overdose
  • Digital gangrene in a woman with scleroderma
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire